Double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of maintenance therapy with anti-TA-MUC1 monoclonal antibody PankoMab after chemotherapy in patients with recurrent epithelial ovarian carcinoma.

Abstract

TPS5622 Background: PankoMab is a potent humanized glyco-engineered IgG1 recognizing the tumor-specific carbohydrate/protein epitope TA-MUC1 expressed virtually only on tumor cells of a wide variet...